FoundationOne®CDx (F1CDx)
FDA premarket approval P170019/S052 · decided 2024-08-30
Approval details
- PMA number
- P170019
- Supplement
- S052
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Trade name
- FoundationOne®CDx (F1CDx)
- Generic name
- Next generation sequencing oncology panel, somatic or germline variant detection system
- Applicant
- Foundation Medicine, Inc.
- Date received
- 2023-12-19
- Decision date
- 2024-08-30
- Days to decision
- 255 days
- Decision code
- APPR
- Product code
- PQP
- Advisory committee
- Pathology
- Expedited review
- No
- Location
- Boston, MA
- Statement
- Approval order to expand the intended use of FoundationOne CDx (F1CDx) (P170019/S052) and FoundationOne Liquid CDx (F1LCDx) (P190032/S016) to include a companion diagnostic indication to identify patients with prostate cancer with BRCA1/2 alterations for the treatment with LYNPARZA (olaparib) in combination with abiraterone.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.